<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2466">
  <stage>Registered</stage>
  <submitdate>18/08/2009</submitdate>
  <approvaldate>18/08/2009</approvaldate>
  <nctid>NCT00963885</nctid>
  <trial_identification>
    <studytitle>A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection</studytitle>
    <scientifictitle>A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Na√Øve Patients With Hepatitis C Genotype 1 Virus Infectio</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-009608-38</secondaryid>
    <secondaryid>NV21075</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Copegus
Treatment: drugs - Pegasys
Treatment: drugs - Placebo
Treatment: drugs - Placebo
Treatment: drugs - RO5190591 (Danoprevir)
Treatment: drugs - RO5190591 (Danoprevir)
Treatment: drugs - RO5190591 (Danoprevir)
Treatment: drugs - RO5190591 (Danoprevir)

Placebo Comparator: Part 1: Placebo - Placebo in combination with standard doses of Pegasys and Copegus.

Experimental: Part 1: RO5190591 300mg po - RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.

Experimental: Part 1: RO5190591 600mg po - RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Experimental: Part 1: RO5190591 900mg po - RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Placebo Comparator: Part 2: Placebo - If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.

Experimental: Part 2: RO5190591 300mg po - If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.


Treatment: drugs: Copegus
1000 or 1200mg po daily for 24 or 48 weeks

Treatment: drugs: Pegasys
180micrograms sc weekly for 24 or 48 weeks

Treatment: drugs: Placebo
po for 12 weeks

Treatment: drugs: Placebo
po for 24 weeks

Treatment: drugs: RO5190591 (Danoprevir)
300mg po q8h for 12 weeks

Treatment: drugs: RO5190591 (Danoprevir)
600mg po q12h for 12 weeks

Treatment: drugs: RO5190591 (Danoprevir)
900mg po q12h for 12 weeks

Treatment: drugs: RO5190591 (Danoprevir)
300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virological response</outcome>
      <timepoint>24 weeks after end of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Virological response over time</outcome>
      <timepoint>At 2- to 6-weekly intervals throughout study; at end of treatment; 12 weeks post-treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events; laboratory parameters</outcome>
      <timepoint>Throughout study, laboratory parameters every 2 to 6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients, &gt;=18 years of age;

          -  chronic hepatitis C, genotype 1;

          -  treatment-naive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  liver cirrhosis and other forms of liver disease;

          -  HIV infection;

          -  hepatocellular cancer;

          -  cardiac disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>229</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital> - Kingswood</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Heidelberg</hospital>
    <postcode> - Kingswood</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt Am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with
      RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and
      Copegus alone, in treatment-naive patients with chronic hepatitis C genotype 1 virus
      infection.In Part 1 of the study, patients will be randomized to receive either 1) RO5190591
      300mg po every 8 hours, 2) RO5190591 600mg po every 12 hours, 3) RO5190591 900mg po every 12
      hours or 4) placebo, in combination with standard doses of Pegasys and Copegus. If the safety
      and virological response data from Part 1 of the study are supportive, in Part 2 patients
      will be randomized to receive either 1) RO5190591 300mg po every 8 hours or 600mg po every 12
      hours or 900mg po every 12 hours or 2)placebo, in combination with standard doses of Pegasys
      and Copegus. The anticipated time on study treatment is 24-48 weeks, and the target sample
      size is 100-500 individuals.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00963885</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>